Most Read Articles
3 months ago
New drug applications approved by US FDA as of 1 - 15 February 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Catherine J Calderwood, MA (Cantab), MRCOG; Omar I Thanoon, MRCOG, 3 years ago

One of the many early physiological adaptations of pregnancy involves changes in the coagulation system, which promote coagulation and impair fibrinolysis. The physiological goal is to prepare for the haemostatic challenge of delivery. A ‘side effect’ of this change is an increased risk of thrombosis. All pregnant women are therefore at risk of thrombosis, compared with non-pregnant women. This risk is manifest from early in the first trimester until 4−6 weeks post partum.

one year ago
Routine laboratory factors predict adverse pregnancy outcomes of patients with intrahepatic cholestasis of pregnancy, according to a prospective, case control study.

Product Highlight - Basalog

5 months ago
BASALOG – Insulin glargine (rDNA) 100 IU/mL soln for inj (cartridge) – CCM Pharmaceuticals

A quality alternative of basal insulin for effective HbA1C control:1-4

  • Equivalent to innovator in terms of:1-4
    • Safety: Reduced risk of nocturnal hypoglycemia1-4
    • Efficacy: Long lasting effect for 24 hours blood glucose control1-4
  • Approved in Japan and more than 20 other countries4
  • Does not contain ingredient derived from animal origin4

References:
1. Verma M., Hazra P., Iyer H., et al., Basalog® is similar to Lantus® in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens. Int J Diabetes Dev Ctries. 2011; 31(1):26–31.
2. Biocon S. A., Phase 3 Study of FFP-112 in Patients with Type I Diabetes Under Intensive Insulin Therapy, 2014.
3. Basalog® Package Insert. 4. Data on file, Biocon Limited.

  • Further information is available in section 11b, New In This Issue and mims.com.
    Full prescribing information is available upon request.
  • Related MIMS Drugs

    Digital Edition
    Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
    DOWNLOAD
    Editor's Recommendations
    Most Read Articles
    3 months ago
    New drug applications approved by US FDA as of 1 - 15 February 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
    one year ago
    New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
    Catherine J Calderwood, MA (Cantab), MRCOG; Omar I Thanoon, MRCOG, 3 years ago

    One of the many early physiological adaptations of pregnancy involves changes in the coagulation system, which promote coagulation and impair fibrinolysis. The physiological goal is to prepare for the haemostatic challenge of delivery. A ‘side effect’ of this change is an increased risk of thrombosis. All pregnant women are therefore at risk of thrombosis, compared with non-pregnant women. This risk is manifest from early in the first trimester until 4−6 weeks post partum.

    one year ago
    Routine laboratory factors predict adverse pregnancy outcomes of patients with intrahepatic cholestasis of pregnancy, according to a prospective, case control study.